ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2291

The Relationship of the ESSDAI to Health-Related Quality of Life in People Living with Sjogren’s Disease

Dana DiRenzo1, Chadwick Johr1, Nora Sandorfi1, Sara McCoy2 and Thomas Grader-Beck3, 1University of Pennsylvania, Philadelphia, PA, 2University of Wisconsin, Middleton, WI, 3Johns Hopkins, Baltimore, MD

Meeting: ACR Convergence 2024

Keywords: Outcome measures, quality of life, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Sjögren's Syndrome – Basic & Clinical Science Poster II

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Historically, Heath Related Quality of Life (HRQL) in Sjogren’s Disease (SjD) has been measured by the EULAR Sjogren’s Syndrome Patient Reported Index (ESSPRI), which lacks important life impact domains. The Patient Reported Outcome Measurement Information System (PROMIS) offers a wider array of HRQL assessments, which were administered to patients alongside the Routine Assessment of Patient Index Data-3 (RAPID-3), a disability measure given to all patients during triage. Our objective was to evaluate the relationship between ESSPRI, PROMIS domains, and SjD disease activity with the hypothesis that there would be moderate positive correlation between PROs and disease activity.

Methods: A prospective study was conducted from November 2022 to September 2023 at a large academic medical center and gathered disease characteristic, disease activity, and patient reported outcome (PRO) data. PROs (ESSPRI, PROMIS-29, RAPID-3) were automatically assigned to SjD patients before their clinic visit and completed via the Epic patient portal. ACR/EULAR 2016 SJD criteria and the EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI) were completed and documented by rheumatologists via Epic smartforms. Mean demographics, disease activity, and HRQL scores were calculated for the first visit within the 6-month study period as well as Spearman and partial correlations to evaluate construct validity.

Results: There were 729/956 (76%) completed ESSPRIs during the study period collected from 594 unique patients. Of those, 197 patients met ACR/EULAR SjD criteria (33%) and had partially completed PROs/ESSDAI and 69 patients had fully completed PROs/ESSDAI. Patients had a mean (SD) age of 61 (14), were mostly female (91%) and white (96%). Mean (SD) ESSDAI scores were 2.1 (3.7) indicating low SjD disease activity with the most active subdomain being biological (n=10 (14%)). Mean (SD) ESSPRI scores were 4.9 (2.4) and considered as borderline-high symptom burden (≥5). There was moderate disability present (mean (SD) RAPID-3, 10.1 (3.7). Mean (SD) PROMIS pain interference and fatigue were greater than one-half SD higher than US population normative values (Table 1). Mood disturbance was not present as reflected by normal anxiety and depression mean T-scores. The total mean ESSPRI score and each of its domains (dryness, fatigue, pain) as well as PROMIS pain interference, fatigue, social participation, and physical function all poorly correlated with the mean ESSDAI score (Table 2A). ESSPRI fatigue displayed better positive correlation with PROMIS pain interference than PROMIS fatigue and vice versa (Table 2B). The ESSPRI total score had strong positive correlation with the RAPID-3, PROMIS pain interference, and fatigue and strong negative correlation with PROMIS social participation. ESSPRI dryness had low/moderate correlation with other HRQL domains.

Conclusion: The ESSDAI lacked significant correlation to all PROs tested suggesting that patient symptomatology is complex and not solely connected to SjD disease activity. Contrary to expected, there was only moderate positive correlation for PROMIS pain interference and ESSPRI pain and PROMIS fatigue and ESSPRI fatigue.

Supporting image 1

Table 1. Characteristics of included people living with Sjogren’s Disease (2016 ACR/EULAR Criteria) who had complete data.

Supporting image 2

Table 2. A) Partial Correlations of the ESSPRI, RAPID_3, and PROMIS domains to the ESSDAI. B) Spearman Correlation of ESSPRI total score and subdomains to PROMIS HRQL domains. * Denotes p<0.5.


Disclosures: D. DiRenzo: None; C. Johr: Bristol-Myers Squibb(BMS), 1, 2; N. Sandorfi: Bristol-Myers Squibb(BMS), 2, Novartis, 1; S. McCoy: Amgen, 2, Bristol-Myers Squibb(BMS), 2, icell, 2, Kiniksa, 2, Novartis, 2, Otsuka/Visterra, 2, Target RWE, 2; T. Grader-Beck: Argenx, 1, 2, Novatis, 1, 2.

To cite this abstract in AMA style:

DiRenzo D, Johr C, Sandorfi N, McCoy S, Grader-Beck T. The Relationship of the ESSDAI to Health-Related Quality of Life in People Living with Sjogren’s Disease [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-relationship-of-the-essdai-to-health-related-quality-of-life-in-people-living-with-sjogrens-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-relationship-of-the-essdai-to-health-related-quality-of-life-in-people-living-with-sjogrens-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology